Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.56 |
| ▸ | ABL1 | P00519 | 19/20 | 0.56 |
| ▸ | EGFR | P00533 | 19/20 | 0.56 |
| ▸ | HCK | P08631 | 19/20 | 0.56 |
| ▸ | SRC | P12931 | 19/20 | 0.56 |
| ▸ | KDR | P35968 | 19/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 19/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 19/20 | 0.56 |
| ▸ | MTOR | P42345 | 19/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 19/20 | 0.56 |
| ▸ | PRKDC | P78527 | 19/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 15/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 18/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9010 | 0.89 | PIK3CG (0.54) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL21467053 | 0.87 | PIK3CG (0.52) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL21467104 | 0.84 | PIK3CD (0.54) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL16655157 | 0.84 | PIK3CD (0.47) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL16665803 | 0.84 | PIK3CD (0.57) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL20093476 | 0.82 | VRK1 (0.41) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL10811 | 0.81 | SRC (0.57) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL11325 | 0.80 | PIK3CG (0.49) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL20793723 | 0.79 | FAAH (0.40) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL20748491 | 0.78 | PIK3CG (0.54) | PIK3CDABL1EGFRHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-06-18 | — | — | US | disclosed |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-10220035-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | PIK3CD 2/4885ABL1 329/4885EGFR 929/4885 |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKAR2B | PIK3CD 89/4885ABL1 464/4885EGFR 1502/4885 |
| US-10220035-B2 | Compounds as modulators of protein kinases | PRKCA, PRKCH, PRKCE | PIK3CD 30/4885ABL1 297/4885EGFR 1203/4885 |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PIK3CD 47/4885ABL1 334/4885EGFR 1359/4885 |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | PIK3CD 2/4885ABL1 62/4885EGFR 828/4885 |
| US-20120208799-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CD 4224/4885ABL1 2202/4885EGFR 3853/4885 |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | MAP3K1, CSNK1A1, MAP3K2 | PIK3CD 148/4885ABL1 376/4885EGFR 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.